Editorial Commentary
Immunohistochemistry as a tool for screening rare renal cancers
Abstract
Recent additions of succinate dehydrogenase (SDH) and hereditary leiomyomatosis and renal cell cancer (HLRCC, associated) fumarate hydratase (FH)-deficient renal cell carcinomas (RCC) to the 2016 WHO Classification of Renal Tumours (1) have highlighted an evolving need for the distinction between renal cancer subtypes.
